日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study

在日本，伊布替尼治疗慢性淋巴细胞白血病患者的真实世界疗效和安全性：Orbit 研究

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-024-03875-0
Muta, Tsuyoshi; Masamoto, Yosuke; Yamamoto, Go; Kurahashi, Shingo; Kameoka, Yoshihiro; Ota, Shuichi; Matsuki, Eri; Ozeki, Kazutaka; Toyama, Takanori; Takahashi, Naoki; Kumode, Takahiro; Aotsuka, Nobuyuki; Yoshimura, Takuro; Tamura, Hideto; Omi, Ai; Shibayama, Kazuhiro; Watanabe, Aki; Isobe, Yasushi; Kojima, Kensuke; Takizawa, Jun; Nagai, Hirokazu; Suzumiya, Junji; Aoki, Sadao
白血病
细胞生物学
发表日期：2025
文献求助 收藏

A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM

一项针对日本复发/难治性多发性骨髓瘤患者的 1/2 期研究，评估了人源化 BCMA × CD3 双特异性抗体 teclistamab 的疗效。

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-024-03884-z
Ishida, Tadao; Kuroda, Yoshiaki; Matsue, Kosei; Komeno, Takuya; Ishiguro, Takuro; Ishikawa, Jun; Ito, Toshiro; Kosugi, Hiroshi; Sunami, Kazutaka; Nishikawa, Kazuko; Shibayama, Kazuhiro; Aida, Kensuke; Yamazaki, Hiroshi; Inagaki, Mitsuo; Kobayashi, Hisanori; Iida, Shinsuke
多发性骨髓瘤
CD3
骨髓瘤
发表日期：2025
文献求助 收藏

Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study

阿帕鲁胺治疗日本非转移性去势抵抗性前列腺癌患者的疗效和安全性：一项随机、双盲、安慰剂对照的3期研究的亚组分析

期刊:Prostate International
影响因子:2.6
doi:10.1016/j.prnil.2020.05.002
Uemura, Hiroji; Satoh, Takefumi; Tsumura, Hideyasu; Arai, Gaku; Imanaka, Keiichiro; Shibayama, Kazuhiro; Fujii, Koji; Rooney, Brendan; Lopez-Gitlitz, Angela; Espina, Byron; Perez-Ruixo, Carlos; Small, Eric J; Smith, Matthew
肿瘤
前列腺癌
肿瘤免疫
发表日期：2020
文献求助 收藏

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study

醋酸阿比特龙联合泼尼松治疗日本新诊断的转移性激素敏感型前列腺癌患者的疗效和安全性：LATITUDE研究（一项随机、双盲、安慰剂对照的3期临床试验）的最终亚组分析

期刊:Japanese Journal of Clinical Oncology
影响因子:2.2
doi:10.1093/jjco/hyaa030
Suzuki, Hiroyoshi; Shin, Toshitaka; Fukasawa, Satoshi; Hashine, Katsuyoshi; Kitani, Sumiko; Ohtake, Noriyuki; Shibayama, Kazuhiro; Tran, Namphuong; Mundle, Suneel; Fizazi, Karim; Matsubara, Nobuaki
肿瘤
肿瘤免疫
LAT
前列腺癌
免疫/内分泌
发表日期：2020
文献求助 收藏

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.

trebananib (AMG 386) 是一种针对血管生成靶向血管生成素-1/2 拮抗剂的药物，在日本晚期实体瘤患者中进行的 1 期研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-012-2000-1
Doi Toshihiko, Ohtsu Atsushi, Fuse Nozomu, Yoshino Takayuki, Tahara Makoto, Shibayama Kazuhiro, Takubo Takatoshi, Weinreich David M
肿瘤
Angiogenesis
血管生成
发表日期：2013
文献求助 收藏